For decades, Argentina had a great historical engine of development: the countryside. Thanks to the economic direction driven by President Javier Milei, strategic sectors such as energy and mining are expanding again, attracting investments and projecting long-term growth. That same paradigm shift is finally allowing another key sector to unleash its full potential: health.
In the last 25 years, the health sector in Argentina has been marked by distortions, lack of clear rules, and a model that discouraged investment and competition. Argentina tried to maintain a complex healthcare system without generating the necessary conditions for it to grow, innovate, and invest sustainably. This model ended up harming everyone: patients, professionals, and also the development of the sector itself.
Today, with the macroeconomic order, stability, and predictability that the National Government is promoting, that has started to change. Health is consolidating as one of the most dynamic sectors of the Argentine economy: it generates highly qualified employment, drives innovation, develops technology, produces knowledge, and exports to the world. Because when the State organizes and establishes clear rules, the private sector invests, incorporates technology, expands capacities, and generates value. The role of the State is not to replace private initiative. It is to create the conditions for it to grow.
Talking about health is not just talking about hospitals or medications. It is a much broader ecosystem: pharmaceutical and biotechnology industry, clinical research, healthcare infrastructure, medical insurance, artificial intelligence applied to health, knowledge-based services, medical technology, diagnosis, and export of professional services.
That is why, following the President's decision, one of the first determinations from the Ministry of Health was to advance in order, competition, and efficiency. The purchase of medications at laboratory exit prices eliminated intermediaries that had unnecessarily increased public spending for years. Lower costs, more competition, and better conditions for investment: that is the standard we seek to consolidate.
And the results are starting to show. So far this year, companies like SC Johnson, Pfizer, and Sinergium Biotech have already announced investments in the country. The Argentine pharmaceutical and biotechnology industry now produces more than 8.1 billion dollars annually and exports to over a hundred countries. The development of biosimilars positions Argentina as a competitive player within increasingly relevant global supply chains in the new international scenario.
